Factors determining remission of microprolactinomas after dopamine agonist withdrawal
Jake Powrie(Guy's and St Thomas' NHS Foundation Trust), N. Athauda(Guy's and St Thomas' NHS Foundation Trust)
23rd Joint Meeting of the British Endocrine Societies with the European Federation of Endocrine Societies
March 1, 2004
Cited by 0
Related Papers
Blood and Islet Phenotypes Indicate Immunological Heterogeneity in Type 1 Diabetes
|Diabetes|2014|244
Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes
|Science Translational Medicine|2017|215
Peripheral and Islet Interleukin-17 Pathway Activation Characterizes Human Autoimmune Diabetes and Promotes Cytokine-Mediated β-Cell Death
|Diabetes|2011|213
Self‐monitoring in Type 2 diabetes mellitus: a meta‐analysis
|Diabetic Medicine|2000|177
Detection of growth hormone abuse in sport
|Growth Hormone & IGF Research|2007|144